

Contents

List of Contributors *XVII*

Foreword *XXI*

- 1 Introduction to the Book** *1*
Alexander Schuhmacher, Oliver Gassmann, and Markus Hinder
Reference *8*

- 2 Global Epidemiological Developments** *11*
Stephan Luther and Peter Schmitz
 - 2.1 Introduction *11*
 - 2.2 Model of Epidemiological Transition *12*
 - 2.3 Global Burden of Diseases *15*
 - 2.3.1 Trends in the Distribution of Disease Burden *16*
 - 2.4 Infectious Diseases *20*
 - 2.4.1 (Re-)emerging Infectious Diseases *23*
 - 2.4.2 Neglected Tropical Diseases *26*
 - 2.5 Noncommunicable Diseases *29*
 - 2.6 Antimicrobial Resistance *32*
 - 2.7 Dynamics *35*
References *38*

 - 3 The Value of Pharmaceutical Innovation: Concepts and Assessment** *45*
Sam Salek and Paul Kamudoni
 - 3.1 Introduction *45*
 - 3.2 Concepts and Definitions of Value *46*
 - 3.3 Stakeholder's Perspectives on Value *47*
 - 3.3.1 Drug Regulatory Agencies *47*
 - 3.3.2 Health Technology Assessment *47*
 - 3.3.3 Patients *49*
 - 3.3.4 Prescribers/Clinicians *49*
 - 3.4 Recent Developments Influencing the Definition and Assessment of Value *50*

3.5	Recommendations: Implications for R&D	51
3.6	Discussion	52
3.7	Conclusion	56
	References	57
4	A Review of the Pharmaceutical R&D Efficiency: Costs, Timelines, and Probabilities	61
	<i>Alexander Schuhmacher, Oliver Gassmann, and Markus Hinder</i>	
4.1	Introduction	61
4.2	The Historical Perspective	62
4.3	The R&D Phase Model	63
4.4	The Low R&D Success Rates	63
4.5	The Long R&D Time Intervals	67
4.6	The High Cost of Pharmaceutical R&D	71
4.7	The Reduced R&D Efficiency	73
4.8	Can an Increase in R&D Value Compensate the Reduced R&D Efficiency?	76
	References	78
5	Financing Pharmaceutical Innovation	81
	<i>Sviataslau Sivagrakau</i>	
5.1	Introduction	81
5.2	Measuring Innovation: Categories of New Drugs	84
5.3	Productivity of Pharmaceutical Industry throughout Time	86
5.4	Measuring the Cost of Developing New Medicines	87
5.5	Funding Drug Development: a Global Endeavor	91
5.6	Public and Private Funds: Complementary Finance for Drug Development	95
5.7	How Commercial Drug Development Projects Are Financed Today: Big Firms, Small Firms, and Their Cooperation	97
5.8	Public Health Economics and Financing Pharmaceutical Innovation	99
5.9	Conclusion	101
	Acknowledgment	102
	References	102
6	Challenges and Options for Drug Discovery	107
	<i>Werner Kramer</i>	
6.1	Introduction	107
6.2	Paradigm Shifts of R&D Organizations	108
6.3	Productivity of Drug Discovery	109
6.4	Is There an Innovation Gap in Biomedical Research?	111
6.4.1	To Go for First in Class or Best in Class	112
6.4.2	How We Define Medical Innovation?	112

6.5	Why Did Drug Candidates Fail? 113
6.5.1	Why Is the Dropout Rate So High in Early Clinical Development? 115
6.5.1.1	Drug Behavior <i>In Vivo</i> : Role of Transport Proteins 115
6.5.1.2	Hypes and Lack of Scientific Thoroughness 116
6.6	Implications from the "Lessons Learnt" for Future Drug Discovery Research 123
6.6.1	Organization of Drug Discovery and Development 123
6.6.2	Elucidation of the Physiological Validity of a Target for the Human Disease 125
6.6.2.1	Extensive Inquiry of (All) Published Data of a Target or Pathway 125
6.6.2.2	Integrative Knowledge Management 127
6.6.2.3	Demonstration of the Involvement of a Target in Human Disease 128
6.6.2.4	A Stringent and Comprehensive Test Sequence 132
6.6.2.5	Translational Clinical Trials 135
	Acknowledgment 136
	References 136
7	Translational Medicine: Enabling the Proof of Concepts 141 <i>Gezim Lahu and John Darbyshire</i>
7.1	Introduction 141
7.2	Translational Medicine and Its Role/Value in Early Development 143
7.3	Knowledge Generation 144
7.4	Types of Data, Experiments, and Tools Needed to Move from Basic Research to Early Clinical Development 144
7.4.1	Dose Selection 145
7.4.2	Animal Models 146
7.4.3	Fraction of NOAEL and Efficacious Dose 149
7.4.4	Allometric Scaling and PBPK 150
7.4.5	Physiologically Based Pharmacokinetic Models PBPK 151
7.4.6	Pharmacokinetic and Pharmacodynamic Modeling 151
7.5	FIM (Dose Escalation and MTD) 153
7.6	Proof of Concept (PoC) 154
	Summary 156
	References 157
8	Preclinical Safety and Risk Assessment 161 <i>Paul Germann and Rob Caldwell</i>
8.1	Introduction 161
8.2	Test Systems 161
8.2.1	<i>In Silico</i> Analysis 161
8.2.2	<i>In Vitro</i> Experiments 162

8.3	Case Study: hERG Assay	163
8.3.1	<i>In Vivo</i> Experiments	164
8.4	The Preclinical "Package" during the Development of an NME	165
8.5	Factors Influencing the Preclinical Data Set	166
8.5.1	Timing and Costs	167
8.5.2	Intended Clinical Application Route	167
8.5.3	Treatment Duration and Treatment Frequency	167
8.5.4	Clinical Indication	167
8.5.5	Ongoing Changes of the Regulatory Landscape	168
8.5.6	New Drug Formats	168
8.6	Translation into Humans: The "Therapeutic Window"	169
8.7	Influence of Intended Therapeutic Use on the Risk Assessment (RA)	169
8.8	Deep Dive Case Study: Safety Assessment of Biological Drug Formats	170
8.9	NBE Case Study 1	175
8.10	NBE Case Study 2	175
8.11	Carcinogenicity Risk Assessment for Marketed Drugs	176
8.12	Treatment Duration	178
8.13	Conclusion – the "Art" of Preclinical Safety: Summarizing the Concept of Hazard Identification and Description, Risk Assessment, and Risk Management	179
	Acknowledgment	179
	Disclosures	180
	References	180
9	Developing Commercial Solutions for Therapeutic Proteins	183
	<i>Galina Hesse</i>	
9.1	Introduction	183
9.2	Developing Commercial Solutions for Therapeutic Proteins	184
9.2.1	Defining a Target Product Profile	184
9.2.2	Developing Formulations for Therapeutic Proteins	186
9.2.3	Testing Formulations for Therapeutic Proteins	188
9.2.4	Development of Primary Containers	188
9.2.5	Development of Application Systems	190
9.3	Quality by Design	192
9.4	Examples for Innovations in Manufacture of Sterile Pharmaceutical Products	194
9.5	Summary	197
	List of FDA/ICH Guidances Referenced	198
	Disclaimer	199
	References	199

10	The Evolution of Clinical Development: From Technical Success to Clinical Value Creation	203
	<i>Markus Hinder and Alexander Schuhmacher</i>	
10.1	Introduction	203
10.2	CD: Changes and Challenges	204
10.2.1	Clinical Endpoints: From Symptom-Oriented Endpoints to Hard and Predefined Endpoints	204
10.2.2	Determination and Quantification of Risks	205
10.2.3	Assessment of Medical Progress in Context of Available Therapeutic Options	206
10.2.3.1	EbM	206
10.2.3.2	Health Economics, Pharmacoeconomics, and the Fourth Hurdle	207
10.2.3.3	Results of These Changes and Challenges	208
10.3	Technical Success and Clinical Value Creation in CD in the Future	208
10.3.1	Established and Novel Approaches to Determine the Dose–Exposure–Response Relationship	210
10.3.2	Comparators	212
10.3.3	Patient Stratification to Increase Treatment Response and Benefit and Reduce Risk	212
10.3.4	New Operational Tools to Succeed in Trials with Increased Complexity, Special Populations, or Large Size	213
10.3.5	Collaboration and Outsourcing as Tools to Work in Networks	214
10.3.6	Collaboration across Sectors and Industries to Boost the Next Wave of Innovation	215
	Disclaimer	218
	References	218
11	Translational Development	225
	<i>Nigel McCracken</i>	
11.1	Introduction	225
11.1.1	Legacy	226
11.2	Translational Development	227
11.2.1	TP	228
11.2.2	Translational Toolkit	229
11.3	Dose Optimization	230
11.3.1	Physicochemical Properties	231
11.3.2	Target Affinity and Selectivity	231
11.3.3	Clearance	231
11.3.4	Prediction of Human Dose	232
11.4	Pharmacogenomics	233
11.4.1	Patient Segmentation	233
11.4.2	Disease Segmentation	234
11.4.3	Utility	237

11.5	Biomarker Development	238
11.5.1	Biomarker Activities	239
11.5.2	Assessing the Opportunity	239
11.6	Systems Pharmacology	240
11.7	Rational Drug Development	241
11.8	Concluding Remarks	242
	References	242
12	Forty Years of Innovation in Biopharmaceuticals – Will the Next 40 Years Be as Revolutionary?	245
	<i>Mathias Schmidt, Sanjay Patel, Petter Veiby, Qiang Liu, and Michael Buckley</i>	
12.1	Introduction	245
12.1.1	The Value Proposition of Biologics	246
12.1.1.1	The Patient Perspective	246
12.1.1.2	The Pharmaceutical Industry’s Perspective	248
12.1.2	Biosimilars: A Blessing or a Threat to Innovation?	250
12.1.3	Further Innovation in Biologics – Incremental or Revolutionary?	252
12.2	The Evolution of Biologics Manufacturing	252
12.2.1	Introduction	252
12.2.2	CHO Cells: The Industry Workhorse	253
12.2.3	Protein Production Strategies	253
12.2.4	The Impact of Increasing Titters on Manufacturing Facilities	255
12.2.5	Protein Purification Platforms	256
12.2.6	Conclusion: What Will the Next 40 Years of Innovation Bring?	258
12.3	The Evolution of Alternative Scaffolds	259
12.3.1	Novel Small Protein Scaffolds	260
12.3.2	Single-Chain Fragment Variables and Diabodies	260
12.3.3	Single-Domain Antibodies	261
12.3.4	Nonantibody Scaffolds	261
12.3.5	Bispecific Single-Chain Fragment Variables and Diabodies	263
12.3.6	Other Bispecific Antibody Formats	264
12.4	Antibody-Drug Conjugates	265
12.5	The Next Wave of Biologics	270
12.5.1	Orally Available Biologics	271
12.5.2	Biologics That Enter the Cytoplasm	271
12.5.3	Biologics That Pass the Blood–Brain Barrier	272
12.5.4	Translational Medicine as Driver of Innovation	272
	Disclaimer	273
	References	273
13	Vaccines: Where Inertia, Innovation, and Revolution Create Value, Simultaneously and Quietly	277
	<i>Pierre A. Morgon and Hannah Nawi</i>	
13.1	Introduction	277

13.2	The World of Vaccines	278
13.2.1	What Are Vaccines?	278
13.2.2	Current Vaccines Are Mainly Prophylactic: Curative Vaccines Are Emerging	278
13.2.3	Drivers to Immunize: Individual and Collective	280
13.2.4	The Pivotal Role of Recommendations	280
13.3	The Vaccine Market: Substantial, Fast Growing, with Intense and Concentrated Competition	281
13.4	The Vaccine Industry: Domination of the Heavyweights, for Now...	282
13.4.1	Barriers to Entry: From R&D Risk to Capital Intensiveness	290
13.4.2	Five Forces Analysis: Competitive Intensiveness and Downstream Hurdles	291
13.4.2.1	Acceptability	291
13.4.2.2	Accessibility	292
13.4.2.3	Availability	293
13.4.2.4	Affordability	293
13.5	New Vaccine Developments: Strategic Trends and Why Innovation Is Needed All along the Value Chain	295
13.5.1	Where Is Innovation Needed? R&D	296
13.5.2	Where Is Innovation Needed? Manufacturing and Product Improvement	301
13.5.3	Where Is Innovation Needed? Acceptability	301
13.5.4	Where Is Innovation Needed? Accessibility, Both as a Function of Supply (Availability) and Logistics	302
13.5.5	Affordability and Sustainability	303
13.6	Where Will Innovation Come from? Strategy and Players	304
13.6.1	Take-Home Messages	305
	References	306
14	The Patient-Centric Pharma Company: Evolution, Reboot, or Revolution?	309
	<i>Pierre A. Morgon</i>	
14.1	Introduction	309
14.2	Health, Always...	310
14.3	The Mission of the Healthcare Industry	310
14.4	Megatrends Affecting the Strategic Scorecard of the Healthcare Industry	312
14.5	Focus on the Societal Trends and Their Consequences for the Management of Healthcare Innovation	314
14.6	The DNA of the Healthcare Industry: R&D and the Management of Innovation	316
14.7	Societal Expectations for Personalized Medicine	318
14.8	New Players Contributing to Information Management to Substantiate Value Propositions for Novel Therapies	319

14.9	The Role of the Key Stakeholders in Shaping a New Regulatory Framework	323
14.10	The Consequences for the Healthcare Industry in Terms of Governance and Capabilities	325
14.11	The Sustainable Path Forward for the Healthcare Industry	329
14.11.1	Take-Home Messages	331
	References	332
15	The Pharmaceutical Industry is Opening Its R&D Boundaries	335
	<i>Alexander Schuhmacher and Ulrich A. K. Betz</i>	
15.1	Introduction	335
15.2	Open Innovation versus Closed Innovation	336
15.3	Business Models in an Open Innovation Framework	341
15.4	Open Innovation Processes	342
15.5	Capabilities and Attitudes Enabling Open Innovation	344
15.6	Open Innovation in the Pharmaceutical Industry	345
15.6.1	The More Traditional Elements of Open Innovation	345
15.6.1.1	Target Scouting	345
15.6.1.2	Research Collaborations	346
15.6.1.3	Drug Licensing	346
15.6.1.4	Outsourcing	348
15.6.1.5	Joint Ventures	349
15.6.2	The Newer Concepts of Open Innovation	349
15.6.2.1	New Frontier Science	350
15.6.2.2	Drug Discovery Alliances	350
15.6.2.3	Private–Public Partnerships	351
15.6.2.4	Innovation Incubator	351
15.6.2.5	Virtual R&D	352
15.6.2.6	Crowdsourcing	353
15.6.2.7	Open Source Innovation	355
15.6.2.8	Innovation Camps	355
15.6.2.9	Fluctuating Open Teams	356
15.7	New Business Models in View of the Potential of Open Innovation	356
15.7.1	General Trends in the Pharmaceutical Industry	356
15.8	Outlook	358
	References	359
16	Out-Licensing in Pharmaceutical Research and Development	363
	<i>Oliver Gassmann, Carol A. Krech, Martin A. Bader, and Gerrit Reepmeyer</i>	
16.1	Introduction	363
16.2	Performance-Based R&D Collaborations on the Rise	364
16.3	The Impact of Collaborations on the Value Chain	365
16.4	Generating Value from Pipeline Assets by Out-Licensing	367
16.5	Pharmaceutical Companies' Resistance toward Out-Licensing	372

16.6	Managing Out-Licensing at Novartis: A Case Study	372
16.6.1	Out-Licensing as a 10-Step Process	373
16.6.2	Out-Licensing Contract Design	375
16.6.3	Structure of the Out-Licensing Collaboration with Speedel	375
16.7	Future Directions and Trends	377
	References	378
17	Trends and Innovations in Pharmaceutical R&D Outsourcing	383
	<i>Antal K. Hajos</i>	
17.1	Introduction	383
17.2	Drivers to the Use of Outsourcing	383
17.2.1	Overview on the CRO Market	383
17.2.2	Core versus Noncore Activities	387
17.3	Genesis of Outsourcing in the Twentieth Century: From Commodity to Contribution	388
17.3.1	Outsourcing Portfolio and the Move to Full-Service Provision	388
17.3.2	Globalization and the Emerging Market Hype	389
17.3.3	Procurement Takes over the Outsourcing Function	391
17.4	Current and Future Trends in Outsourcing: From Contribution to Innovation	392
17.4.1	How Has Outsourcing Itself Innovated and What Are the Future Trends?	392
17.4.2	How Does and Will Outsourcing Contribute to Innovation?	394
17.5	Discussion and Conclusion	395
	References	398
18	New Innovation Models in Pharmaceutical R&D	401
	<i>Alexander Schuhmacher, Oliver Gassmann, and Markus Hinder</i>	
18.1	Introduction	401
18.2	Some Attempts That Were Recommended in the Past	402
18.3	The Increasing Pipeline Size	403
18.4	The Reduction of R&D Investments	404
18.5	The Opening of the R&D Processes	407
18.6	The Challenge with the Return on Investment	411
18.7	Changing the R&D Processes Is Not Enough	412
18.8	What Is the Best R&D Model?	413
	References	414
19	The Influence of Leadership Paradigms and Styles on Pharmaceutical Innovation	416
	<i>Aubyn Howard</i>	
19.1	Introduction	417
19.2	What Is Your Concept or Model of Good Leadership?	419
19.3	Approaches to Leadership Modeling and Profiling	420
19.3.1	Personality Types	421

19.3.2	Behavioral Preferences	421
19.3.3	Developmental Stages	421
19.3.4	Competency Frameworks	421
19.4	The Developmental Approach to Leadership Paradigms and Styles	422
19.5	Inner and Outer Leadership	424
19.6	Dynamics of How Leadership Paradigms Evolve	425
19.6.1	Magic–Animistic	426
19.6.2	Impulsive–Egocentric	427
19.6.3	Conformist–Absolutist	428
19.6.4	Achievement–Multiplistic	429
19.6.5	Pluralistic–Relativistic	430
19.6.6	Evolutionary–Systemic	432
19.7	Leadership at Different Levels within Pharma	433
19.8	Optimizing Innovation in Different Organizational Models and Cultures	437
19.9	How Do We Support the Development of Evolutionary Leaders?	439
19.10	What Does It Mean to Operate from the Evolutionary Paradigm?	440
19.11	Leadership and Personal Mastery	441
19.12	Building an Evolutionary Bridge to Release Innovation	442
19.13	Conclusions	445
	References	446
20	The Role of Modern Portfolio Management in Pharma Innovation	449
	<i>Joachim M. Greuel and Axel Wiest</i>	
20.1	Introduction	449
20.2	Challenges in R&D and the Origin of Pharmaceutical Portfolio Management	450
20.3	Goals and Metrics of Portfolio Management	451
20.4	Portfolio Management as Enabler of Innovation	456
20.5	Modern Portfolio Management Integrates In-House R&D, Business Development, and M&A	457
	References	458
21	Patent Management Throughout the Innovation Life Cycle	461
	<i>Martin A. Bader and Oliver Gassmann</i>	
21.1	Introduction	461
21.2	The Changing Role of Patents: From Legal to Strategic	462
21.3	The Patent Life Cycle Management Model	467
21.3.1	Exploration	468
21.3.2	Generation	469
21.3.3	Protection	469

21.3.4	Optimization	470
21.3.5	Decline	470
21.4	Example: Managing IP Rights at Bayer	471
21.5	Concluding Remarks	472
	References	473
	Index	475

